Racard1.25 mg

Racard 1.25 mg is an angiotensin-converting enzyme (ACE) inhibitor prescribed to manage cardiovascular and renal conditions. It is indicated in the following cases:

• Hypertension: To lower elevated blood pressure, either as a single-drug (monotherapy) treatment or in combination with other antihypertensive agents such as diuretics or calcium channel blockers.
• Congestive heart failure: Used to manage symptomatic heart failure, often in combination with diuretics.
• Post-myocardial infarction heart failure: For the treatment of patients who, within the first few days after an acute myocardial infarction (heart attack), have shown clinical signs of congestive heart failure.
• Diabetic and non-diabetic nephropathy: For the treatment of overt glomerular nephropathy or incipient (early-stage) nephropathy in both diabetic and non-diabetic patients.
• Cardiovascular risk reduction: To reduce the risk of myocardial infarction, stroke, or cardiovascular death in patients at increased cardiovascular risk. This includes patients with manifest coronary heart disease (with or without a prior heart attack), a history of stroke, a history of peripheral vascular disease, or diabetes mellitus accompanied by at least one additional cardiovascular risk factor such as microalbuminuria, hypertension, elevated total cholesterol, low HDL cholesterol, or smoking.

Angiotensin-converting enzyme (ACE) inhibitors.

Racard 1.25 mg is a long-acting angiotensin-converting enzyme (ACE) inhibitor. After oral administration, it is hydrolyzed in the liver to its active metabolite, Racard 1.25 mgat, which is a potent inhibitor of the ACE enzyme.

ACE is responsible for converting angiotensin I into angiotensin II, a powerful vasoconstrictor. By blocking this conversion, Racard 1.25 mg reduces plasma levels of angiotensin II, which leads to two key effects: decreased vasopressor (blood-vessel-narrowing) activity and reduced secretion of aldosterone. The combined result is relaxation of blood vessels and a fall in blood pressure, giving Racard 1.25 mg its antihypertensive action.

Beyond controlling blood pressure, Racard 1.25 mg is effective in the management of heart failure and in reducing the risk of stroke, myocardial infarction, and death from cardiovascular events. Because it is long-acting and generally well tolerated, it is well suited for long-term maintenance therapy.

Racard 1.25 mg may interact with several medicines and substances. Inform your physician of all drugs you are taking before starting treatment.

• Diuretics: Concomitant use may lead to serious hypotension (very low blood pressure).
• Potassium-sparing diuretics and potassium supplements: May cause dangerous hyperkalaemia (elevated blood potassium levels).
• Lithium: Concomitant therapy may increase serum lithium concentrations, raising the risk of lithium toxicity.
• NSAIDs (non-steroidal anti-inflammatory drugs): May reduce the antihypertensive effect of Racard 1.25 mg and cause deterioration of renal function.
• Alcohol: May enhance the blood-pressure-lowering effect, which can impair the ability to drive or operate machinery.

Racard 1.25 mg is generally well tolerated. Most side effects are mild and transient, but patients should report any persistent or severe symptoms to their physician.

• Common: Dizziness, headache, fatigue, and asthenia (weakness).
• Less frequent: Symptomatic hypotension, dry cough, nausea, vomiting, diarrhoea, skin rash, urticaria (hives), oliguria (reduced urine output), anxiety, and amnesia.
• Rare but serious: Angioneurotic oedema (angioedema), anaphylactic reactions, and hyperkalaemia (high blood potassium).

Pregnancy: Racard 1.25 mg must not be taken during pregnancy. Pregnancy should be excluded before starting treatment. If treatment with an ACE inhibitor is unavoidable, pregnancy must be actively avoided. A patient who intends to become pregnant should have ACE inhibitor therapy discontinued and replaced with an alternative treatment. If a patient becomes pregnant during treatment, Racard 1.25 mg must be replaced with a non-ACE-inhibitor regimen as soon as possible, since continued use carries a risk of harm to the fetus.

Lactation: Racard 1.25 mg is not recommended during breastfeeding.

Racard 1.25 mg should be used with caution in patients with the following conditions, who may require closer monitoring:

• Impaired renal (kidney) function.
• Hyperkalaemia (elevated blood potassium levels).
• Hypotension (low blood pressure).
• Impaired hepatic (liver) function.

Signs and symptoms: Overdosage may cause excessive peripheral vasodilatation (with marked hypotension and shock), bradycardia (slow heart rate), electrolyte disturbances, and renal failure.

Management: Primary detoxification—for example, gastric lavage and administration of adsorbents and sodium sulfate—should be carried out if possible within the first 30 minutes. In the event of hypotension, administration of α1-adrenergic agonists (such as norepinephrine or dopamine) or angiotensin II (angiotensinamide) may be considered, in addition to volume and salt replacement. Angiotensinamide is usually available only in specialized research laboratories.

Store at 30°C or below and protect from light. Keep out of the reach of children. Do not use the medicine later than its expiry date. Racard 1.25 mg is to be dispensed only on the prescription of a registered physician.

Elderly

A reduced initial dose of 1.25 mg Racard 1.25 mg daily should be considered.

Hepatic Impairment

Treatment must be initiated only under close medical supervision. The maximum permitted daily dose in these patients is 2.5 mg Racard 1.25 mg.

Renal Impairment

For patients with a creatinine clearance between 50 and 20 ml/min per 1.73 m² of body surface area, the usual initial daily dose is 1.25 mg Racard 1.25 mg, with a maximum permitted daily dose of 5 mg.

Patients at Risk of Marked Hypotension

For patients with incompletely corrected fluid or salt depletion, those with severe hypertension, and those in whom a hypotensive reaction would pose a particular risk (for example, those with relevant stenosis of the coronary or cerebral vessels), a reduced initial dose of 1.25 mg Racard 1.25 mg daily should be considered.

Patients Pretreated With a Diuretic

Discontinuation of the diuretic for at least 2 to 3 days—or longer, depending on its duration of action—should be considered before starting Racard 1.25 mg, or the diuretic dose should at least be reduced. The initial daily dose in these patients is generally 1.25 mg Racard 1.25 mg.

Angiotensin-converting enzyme (ACE) inhibitors

Racard 1.25 mg is an angiotensin converting enzyme (ACE) inhibitor, which after hydrolysis to Racard 1.25 mgat, blocks the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. So, inhibition of ACE by Racard 1.25 mg results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and decreased aldosterone secretion. Thus Racard 1.25 mg exerts its antihypertensive activity. It is also effective in the management of heart failure and reduction of the risk of stroke, myocardial infarction and death from cardiovascular events. It is long acting and well tolerated; so, can be used in long term therapy.

Racard 1.25 mg must not be taken during pregnancy. Therefore, pregnancy must be excluded before starting treatment. Pregnancy must be avoided in cases where treatment with ACE inhibitors is indispensable. If the patient intends to become pregnant, treatment with ACE inhibitors must be discontinued, i.e. replaced by another form of treatment. If the patient becomes pregnant during treatment, medication with Racard 1.25 mg must be replaced as soon as possible by a treatment regimen without ACE inhibitors. Otherwise, there is a risk of harm to the fetus. Racard 1.25 mg is not recommended during breastfeeding.

Elderly: A reduced initial dose of 1.25 mg Racard 1.25 mg daily must be considered.Hepatic impairment: Treatment in these patients must therefore be initiated only under close medical supervision. The maximum permitted daily dose in such cases is 2.5 mg Racard 1.25 mg.Renal impairment: With a creatinine clearance between 50 and 20 ml/min per 1.73 m2 body surface area, the initial daily dose is generally 1.25 mg Racard 1.25 mg. The maximum permitted daily dose, in this case, is 5 mg Racard 1.25 mg. Patients with incompletely corrected fuid or salt depletion, in patients with severe hypertension, as well as in patients in whom a hypotensive reaction would constitute a particular risk, (e.g., with relevant stenoses of the coronary vessels or those supplying the brain) A reduced initial dose of 1.25 mg Racard 1.25 mg daily must be considered.Patients pretreated with a diuretic: Consideration must be given to discontinuing the diuretic for at least 2 to 3 days or- depending on the duration of action of the diuretic- longer before starting treatment with Racard 1.25 mg, or at least to reducing the diuretic dose. The initial daily dose in patients previously treated with a diuretic is generally 1.25 mg Racard 1.25 mg.